NCT00897910

Studying T Cells in Blood and Bone Marrow Samples From Patients With Multiple Myeloma

Strategies to Isolate and Expand Myeloma Specific T-cells Using Autologous B Cells as Antigen Presenting Cell B-APC

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 6 (actual)
• Sponsor: Barbara Ann Karmanos Cancer Institute · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

RATIONALE: Studying samples of blood and bone marrow from patients with cancer in the laboratory may help doctors learn more about T cells and plan better treatment for multiple myeloma. PURPOSE: This research study is looking at T cells in blood and bone marrow samples from patients with multiple myeloma.

Detailed description

OBJECTIVES: Primary * To evaluate the feasibility of expanding myeloma-specific T cells using autologous ex vivo expanded B cells loaded with myeloma antigens as antigen-presenting cells (B-APCs) in peripheral blood and bone marrow samples from patients with multiple myeloma. Secondary * To examine the feasibility of selecting and expanding myeloma-specific T cells ex vivo using interferon γ release and CD3/CD28 stimulation. OUTLINE: Peripheral blood and bone marrow samples are collected periodically for laboratory studies. Samples are analyzed to assess the feasibility of expanding autologous B cells ex vivo using CD40L and IL-4; the antigen-presenting phenotype of autologous B-cell antigen-presenting cells (B-APCs) using flow cytometry; and the antigen-presenting function of B-APCs using ELISPOT and chromium-release assay. Myeloma-specific interferon γ secreting T cells are isolated and selected using Miltenyi beads. The selected myeloma-specific T cells are expanded ex vivo using anti CD3/CD28 beads.

Conditions

• Multiple Myeloma and Plasma Cell Neoplasm

Interventions

Type	Name	Description
OTHER	flow cytometry	Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
OTHER	immunoenzyme technique	Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
OTHER	laboratory biomarker analysis	Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.

Timeline

• Start date: 2008-04-01
• Primary completion: 2009-11-01
• Completion: 2012-09-01
• First posted: 2009-05-12
• Last updated: 2016-01-11
• Results posted: 2013-12-12

Locations

1 site across 1 country: United States